Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
Recruiting
The primary purpose of this study is to evaluate the effectiveness of sivopixant, acetazolamide and SASS-001 in adults with sleep apnea with a central component.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/16/2025
Locations: Huntsville Research Institute LLC, Huntsville, Texas
Conditions: Sleep Apnea
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Recruiting
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumors
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
Recruiting
A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/16/2025
Locations: Research Site, Abilene, Texas
Conditions: Asthma
Lower Extremity Elevation to Minimize Hemodynamic Instability During Induction of General Anesthesia
Recruiting
The purpose of this study is to determine if lower extremity elevation (LEE) will reduce the incidence of postinduction hypotension, to compare the utilization of vasoactive medications after induction in patients with LEE and patients without LEE and to determine if LEE will increase measured cardiac output
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/16/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Post Induction Hypotension
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
Recruiting
Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Houston Methodist, Houston, Texas
Conditions: Acute Kidney Injury
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Local Institution - 0069, Austin, Texas
Conditions: Multiple Myeloma
StrokeNet Thrombectomy Endovascular Platform
Recruiting
STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Memorial Hermann Texas Medical Center, Houston, Texas
Conditions: Ischemic Stroke
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
Recruiting
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/16/2025
Locations: Texas Oncology, Dallas, Texas
Conditions: Advanced Melanoma
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
Recruiting
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).
Gender:
ALL
Ages:
17 years and above
Trial Updated:
06/16/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
Recruiting
A multi-center, prospective, dual arm, randomized, controlled pivotal study to evaluate the safety and effectiveness of the ReGelTec HYDRAFIL™ System.
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
06/16/2025
Locations: Precision Spine Care, Tyler, Texas
Conditions: Degenerative Disc Disease (DDD)
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
Recruiting
The main purpose of the study is to evaluate the safety and tolerability of HRO761 and identify the recommended dose(s), i.e., the optimal safe and active dose of HRO761 alone or in combination with pembrolizumab or irinotecan that can be given to patients who have cancers with specific molecular alterations called MSIhi (Microsatellite Instability-high) or dMMR (Mismatch Repair Deficient) that might work best to treat these specific cancer types and to understand how well HRO761 is able to trea... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/16/2025
Locations: Univ of TX MD Anderson Cancer Cntr, Houston, Texas
Conditions: MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder
Recruiting
To determine sufficient number of biological and clinical markers to identify subgroups of potential best responders to a specific medication
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
06/16/2025
Locations: Red Oak Psychiatry Associates, Houston, Texas
Conditions: Autism Spectrum Disorder